Michael Schöll, PhD, University of Gothenburg, Gothenburg, Sweden, shares his thoughts on the current role of tau-PET in clinical routine. Investigations into tau-PET have demonstrated its value for the early differential diagnosis of dementia, predicting cognitive change more accurately than amyloid-PET or MRI, and as a surrogate outcome measure. While its use has become much more prominent since the approval of the first tau-PET tracer in 2020, tau-PET remains hampered by the lack of validation of visual assessment routines. Prof. Schöll mentions an ongoing study aiming to tackle this, which will collect over 5000 [18F]flortaucipir tau-PET scans and analyze associations between visual assessment features and clinical outcomes. This interview took place at the Alzheimer’s Research UK (ARUK) Conference 2023 in Aberdeen, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
